Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.55 USD
+0.03 (0.85%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $3.56 +0.01 (0.28%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fate Therapeutics (FATE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.83 | $12.00 | $3.50 | 94.03% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Fate Therapeutics comes to $6.83. The forecasts range from a low of $3.50 to a high of $12.00. The average price target represents an increase of 94.03% from the last closing price of $3.52.
Analyst Price Targets (15)
Broker Rating
Fate Therapeutics currently has an average brokerage recommendation (ABR) of 2.48 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 2.48 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, seven are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 12 | 12 | 12 | 12 | 13 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.48 | 2.48 | 2.48 | 2.48 | 2.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/30/2024 | Not Identified | Not Identified | Hold | Hold |
8/27/2024 | Robert W. Baird & Co. | Jack K Allen | Hold | Hold |
8/22/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
8/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/14/2024 | Needham & Company | Gil J Blum | Hold | Hold |
8/13/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
6/17/2024 | Piper Sandler | Edward A Tenthoff | Hold | Strong Buy |
5/16/2024 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
5/10/2024 | BMO Capital Markets | Etzer Darout | Hold | Hold |
5/10/2024 | Canaccord Genuity | William Maughan | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Tara Bancroft | Hold | Hold |
2/27/2024 | Not Identified | Not Identified | Hold | Hold |
2/27/2024 | Cantor Fitzgerald & Co | Li Watsek | Hold | Hold |
1/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/1/2023 | Guggenheim Securities | Michael Schmidt | Hold | Hold |
12/1/2023 | Goldman Sachs | Andrea Tan | Strong Sell | Strong Sell |
11/9/2023 | Wells Fargo Securities | Yanan Zhu | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.48 |
ABR (Last week) | 2.48 |
# of Recs in ABR | 21 |
Average Target Price | $6.83 |
LT Growth Rate | 25.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.42 |